Abstract
Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma.
Highlights
Clinical course, and a 5-year overall survival (OS) of o 10%.1,3 Remissions following donor lymphocyte infusion6–8 and reduced immunosuppression9 suggest potent graft-versus-lymphoma unrelated donor in 33%, haploidentical relative in 8% and cord blood in 6% of transplants
Due to the rarity of the disease and the sporadic nature of the disease (GvHD) prophylaxis was calcineurin based in all patients, available reports, transplant outcomes in this disease are with the addition of post-transplant cyclophosphamide in three unknown
We provide a systematic review of all haploidentical transplants and anti-thymocyte globulin in two previously published reports of allo-SCT in Hepatosplenic T-cell lymphoma (HSTCL) including four patients
Summary
Outcomes of allogeneic stem cell transplantation in hepatosplenic T-cell lymphoma. Blood Cancer Journal (2015) 5, e318; doi:10.1038/bcj.2015.43; published online 5 June 2015. The involvement were present in 35%, 100% and 82% of patients, only variables significantly associated with longer RFS were respectively. Conventional karyotype analysis and/or fluorescence in situ males had shorter OS (Supplementary Figure S1), the hybridization Among these patients, isochromosome 7 (77%) difference did not reach statistical significance (P = 0.11). MA complete remission in 41%, partial remission in 43% and conditioning was associated with longer RFS
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
